Compare AZZ & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AZZ | BEAM |
|---|---|---|
| Founded | 1956 | 2017 |
| Country | US | US |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 2.7B |
| IPO Year | 1994 | 2019 |
| Metric | AZZ | BEAM |
|---|---|---|
| Price | $132.77 | $27.55 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 14 |
| Target Price | ★ $118.00 | $46.00 |
| AVG Volume (30 Days) | 131.5K | ★ 1.5M |
| Earning Date | 04-08-2026 | 04-01-2026 |
| Dividend Yield | ★ 0.60% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 9.97 | N/A |
| Revenue | ★ $1,061,817,000.00 | $24,000.00 |
| Revenue This Year | $5.53 | N/A |
| Revenue Next Year | $5.59 | $22.06 |
| P/E Ratio | $13.32 | ★ N/A |
| Revenue Growth | 14.53 | ★ 33.33 |
| 52 Week Low | $70.90 | $13.53 |
| 52 Week High | $141.18 | $36.44 |
| Indicator | AZZ | BEAM |
|---|---|---|
| Relative Strength Index (RSI) | 60.56 | 48.18 |
| Support Level | $124.97 | $26.20 |
| Resistance Level | $141.18 | $29.26 |
| Average True Range (ATR) | 3.63 | 1.64 |
| MACD | 0.23 | -0.09 |
| Stochastic Oscillator | 54.34 | 59.33 |
AZZ Inc is a provider of galvanizing and a variety of metal coating solutions and coil coating solutions to a broad range of end markets in North America. The company's operating segment consists of Metal Coatings, Precoat Metals, and Infrastructure Solutions. The company generates the majority of its revenue from the Precoat Metals segment, which provides coil coating application of protective and decorative coatings and related value-added downstream processing for steel and aluminum coils. Geographically, the company generates the majority of its revenue from the United States.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.